News | January 24, 2014

CorMatrix Cardiovascular Receives U.S. Patent for Injectable Biomaterial

CorMatrix Cardiovascular Extracellular Matrix ECM Bioscaffold

January 24, 2014 — CorMatrix Cardiovascular Inc. received a patent for an augmented injectable extracellular matrix (ECM) bioscaffold. 
 
The augmented ECM bioscaffold induces stem cell proliferation and differentiation of stem cells into cardiomyocytes, and, thereby, angiogenesis and remodeling of cardiovascular tissue.
 
U.S. Patent No. 8,568,761 is based on one of multiple pending U.S. applications with claims directed toward ECM bioscaffolds that are augmented with a variety of bioactive components, such as TGF-2, TGF-? and DNA.
 
“Capturing and directing stem cell function for truly regenerating tissues requires the appropriate microenvironment, not just stem cells,” said Robert Matheny, M.D., a cardiovascular surgeon and chief scientific officer for CorMatrix. “The future of regenerative therapy will be directed toward enhancing our effective matrices with factors that fully capture and augment regeneration.”
 
CorMatrix has U.S. clearance and CE marking for its ECM technology as an implant for pericardial closure, cardiac tissue repair and carotid repair. It plans to initiate human safety trials for heart failure in Europe early in 2014 with its formula and device for application of the ECM. 
 
Background of Extracellular Matrix (ECM) Biomaterial
The decellularized matrix material serves as a bioscaffold to allow vascular ingrowth from adjacent tissues to deliver progenitor cells and nutrients to the matrix, which then differentiate into tissue-specific cells and structures. The ECM material is gradually replaced as the patient’s own cells reinforces and rebuilds the diseased or damaged site. During repair, the matrix is naturally degraded and resorbed, leaving remodeled functional tissue where damaged or injured tissue may be expected. 
 
For more information: www.cormatrix.com

Related Content

News | Stem Cell Therapies

November 19, 2021 — Stem cell therapy helped to reduce the number of heart attacks, strokes and death among people with ...

Home November 19, 2021
Home
News | Stem Cell Therapies

October 28, 2021 – The first patient has been treated in a new trial using stem cell therapy to treat chronic myocardial ...

Home October 28, 2021
Home
Videos | Stem Cell Therapies

Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical ...

Home October 04, 2021
Home
Feature | Stem Cell Therapies | By Simon H. Stertzer, M.D.

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections ...

Home May 11, 2021
Home
Feature | Stem Cell Therapies | By Andy Freeberg

The University of Washington (UW) in Seattle has developed engineered heart tissue that beats. Though minuscule, the ...

Home February 25, 2021
Home
News | Stem Cell Therapies

August 22, 2019 — Renovacor Inc, a preclinical-stage biopharmaceutical company, announced the successful completion of ...

Home August 22, 2019
Home
News | Stem Cell Therapies

May 20, 2019 – Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from ...

Home May 20, 2019
Home
News | Stem Cell Therapies

April 19, 2019 — Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal ...

Home April 19, 2019
Home
News | Stem Cell Therapies

March 4, 2019 — The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding ...

Home March 04, 2019
Home
News | Stem Cell Therapies

February 1, 2019 — A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts ...

Home February 01, 2019
Home
Subscribe Now